Second shop will help domestic abuse charity expand
A domestic abuse charity is opening its second charity shop, which will help support the organisation to expand across the region.
Society Without Abuse (SWA) is opening the store in Marlborough after success with its first one in Swindon, the town the charity started in 50 years ago.
People are being encouraged to donate and volunteer at the 'Survivor Shop' in the town.
The charity works through education, early intervention and prevention, including teaching about healthy relationships in schools.
More news stories for Wiltshire
Listen to the latest news for Wiltshire
SWA has described it as a "boutique" charity shop, which is opening on 4 June in Marlborough's town centre at Hughenden Yard.
"We're incredibly excited to become part of the Marlborough community," said Kate Rowland, CEO of SWA.
"Our new shop offers not only a wide range of quality pre-loved women's clothing and accessories, as well as the chance for people to make a real difference with every purchase and donation."
She added that the Swindon shop already sells "top quality brands".
Money raised by the shop helps fund the charity's HOPE programme, which works with children and young people to help them recover from the trauma of abuse.
It also has developed Open2Change, a behaviour change programme for those who show unhealthy behaviours towards partners and families, with the aim to stop reoffending.
In addition, the charity offers training in awareness of domestic abuse to help employers meet the needs of their staff.
Follow BBC Wiltshire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Domestic abuse charity to lose refuge centre contract
Domestic violence stays high after Covid - charity
Abuse survivors' art is 'relief from a monster'
Society without Abuse
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Four-year data show preservation of cardiac function, including LVEF Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) Deramiocel's long-term safety profile remains favorable Results presented at PPMD's 2025 Annual Conference SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be featured in the session titled 'Therapies that Slow Progression' at the Parent Project Muscular Dystrophy (PPMD) 2025 Annual Conference, taking place June 21, 2025, in Las Vegas, Nevada. After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline. Further, a subgroup analysis of patients with baseline LVEF >45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function. Additionally, treatment continued to slow skeletal muscle disease progression, as measured by Performance of the Upper Limb (PUL v2.0), with patients experiencing a smaller average decline in the fourth year (0.6 points) compared to the first year (1.8 points). Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study. 'Cardiomyopathy remains one of the leading causes of mortality in Duchenne and addressing this aspect of the disease is critical to improving outcomes,' said Pat Furlong, Founding President and CEO of PPMD. 'The long-term data from the HOPE-2 OLE study are encouraging, particularly in demonstrating cardiac stabilization over four years. Deramiocel represents an important therapeutic approach and we support continued progress through the regulatory pathway to ensure that treatments targeting both heart and muscle function are available to our community as quickly as possible.' 'These four-year data reinforce the strength and durability of Deramiocel's clinical benefit and favorable safety profile across both cardiac and skeletal muscle function,' said Linda Marbán, Ph.D., CEO of Capricor Therapeutics. 'With our BLA under priority review and several key regulatory steps now completed, we are executing with focus and urgency as we move toward potential approval. Our continued dialogue with the FDA remains on track with no evidence of any delays. We thank the patients, families, and clinicians who have been instrumental in advancing this program.' The PPMD Annual Conference is the largest international event focused on advancing research, clinical trials, and standards of care for Duchenne and Becker muscular dystrophies. Capricor's presentation will be available following the conference in the publications section of the Company's was a randomized, double-blind, placebo-controlled Phase 2 study of Deramiocel in boys and young men with Duchenne Muscular Dystrophy (DMD). Patients received intravenous infusions of either Deramiocel (150 million cells) or placebo every three months. The results were published in The Lancet. Following study completion, all patients entered a treatment gap phase for approximately 392 days (range: 239–567). Eligible patients then enrolled in the HOPE-2 OLE study, receiving Deramiocel every three months. The OLE study previously met its primary endpoint at one year with statistically significant improvement on the PUL v2.0 (p=0.02). Now in its fifth year, the HOPE-2 OLE study remains ongoing, with participants continuing to be monitored for safety, cardiac function, and upper limb Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. There is no cure, and treatment options remain (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in dystrophiopathies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing, rather than a pro-inflammatory phenotype. CDCs have been investigated in more than 250 peer-reviewed scientific publications and administered to over 250 human subjects across multiple clinical trials. Deramiocel has received Orphan Drug Designation for the treatment of Duchenne Muscular Dystrophy (DMD) from both the U.S. FDA and the European Medicines Agency (EMA). In addition, it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA, which may qualify Capricor for a Priority Review Voucher upon approval. For Becker Muscular Dystrophy (BMD), Deramiocel has also received Orphan Drug Designation from the Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown Deramiocel to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in muscular dystrophies such as DMD. Deramiocel is currently in late-stage development for the treatment of Duchenne Muscular Dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit and follow Capricor on Facebook, Instagram and in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'believes,' 'plans,' 'could,' 'anticipates,' 'expects,' 'estimates,' 'should,' 'target,' 'will,' 'would' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on May 14, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements. Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug (IND) and is not yet approved for any indications. Neither BMD nor any of Capricor's exosome-based candidates have been approved for clinical Media Contact:Raquel ConaKCSA Strategic Communications rcona@ Capricor Company Contact:AJ Bergmann, Chief Financial Officerabergmann@
Fox News
3 days ago
- Fox News
'Grey's Anatomy' alum Eric Dane prepared to go to extreme measures to fight ALS
Eric Dane is prepared to go to extreme measures to fight ALS. "I will fly to Germany and eat the head off a rattlesnake if [doctors] told me that that would help," the 52-year-old "Grey's Anatomy" alum told Diane Sawyer during a sit-down interview on "Good Morning America." "I'll assume the risk." During the interview, which aired Tuesday, Dane opened up about the debilitating disease and explained how he's found hope in the physician who has been leading his care. "I'm very hopeful... I don't think this is the end of my story," he said. "And whether it is or it isn't, I'm gonna carry that idea with me. "That's what I got from [Dr. Merit Cudkowicz] when I met her... there was a sense of hope I didn't get from other doctors that I met with," Dane said of his doctor, a neurologist and leading ALS researcher. Dane said that he had spoken previously with an organization that told him his doctors would be "there to... monitor my decline — and that's not very helpful." Dr. Cudkowicz said the risk factors behind the disease can include anything from environmental concerns like plastics and bacteria in lakes to sports injuries. "We worry about head trauma because we do see ALS more common in people in certain sports like football or soccer. We worry about pesticides as well. Being in the military is a risk factor," she said. "Those are the ones we know about, but there's many more we don't know about. "There's people all over the world working on this," she said, referring to ALS research. "Between artificial intelligence and other imaging technology, that's what gets me excited, and that's all coming in the next, I think, one to two years, if not faster." Dane, who revealed his diagnosis in April, said in another segment of the interview that aired Monday that he first started experiencing weakness in his right hand before seeking medical attention. "I didn't really think anything of it at the time," he told Sawyer. "I thought maybe I'd been texting too much and my hand was fatigued. A few weeks later, I noticed it'd gotten a little worse. I went and saw a hand specialist, who sent me to another hand specialist. I went and saw a neurologist, and the neurologist sent me to another neurologist and said, 'This is way above my pay grade.' "I have one functioning arm," he said. "My left side is functioning. My right side has completely stopped working. [My left arm] is going. I feel like maybe a couple, a few more months, and I won't have my left hand either. It's sobering." He said that for now, he is able to walk, but added, "I'm worried about my legs." Dane admitted that he will "never forget" the moment he was diagnosed. "I will never forget those three letters, [ALS]. It's on me the second I wake up," he said. "It's not a dream." The actor, who shares two daughters, Billie, 15, and Georgia, 13, with wife Rebecca Gayheart, said he began noticing more of the effects of his disease a few months ago during a boating trip with his daughter. After jumping into the water, Dane — a former competitive swimmer — quickly realized he was not able to swim. "[Georgia] dragged me back to the boat," said Dane, who recalled immediately breaking down in tears once on the boat. "I was just, I was, like, heartbroken." Dane also told Sawyer that he is "angry" about the diagnosis, explaining, "I'm angry because my father was taken from me when I was young, and now there's a very good chance that I'm going to be taken from my girls while they're very young." "I mean, I really, at the end of the day, just, all I want to do is spend time with my family and work a little bit if I can," he added. Fox News Digital's Janelle Ash contributed to this post.
Yahoo
4 days ago
- Yahoo
Hoda Kotb Reunites With Ex Joel Schiffman as They Celebrate Father's Day With Their Daughters at TV Host's Suburban Home
Former 'Today' host Hoda Kotb had a heartfelt reunion when her ex-fiancé Joel Schiffman this weekend, when she welcomed the financier into her suburban home for a Father's Day celebration with their two daughters. The TV host-turned-wellness guru took to Instagram to share sweet images of her former partner enjoying a fun-filled day in and around her Bronxville property, proving that—despite their split—the duo are putting their past behind them in order to focus on co-parenting daughters Haley, 9, and Hope, 5. In one image, Schiffman, 67, could be seen grinning from ear-to-ear while sharing a sweet embrace with his kids inside 60-year-old Kotb's kitchen at her $2.9 million home, which she purchased in April 2024, shortly before she quit the 'Today' show. A second snap showed him strolling hand-in-hand with Hope through what appeared to be a local mall. Kotb, who stepped down from her on-screen role alongside in January, gushed about Schiffman in the caption, penning, 'A great father's day for a great dad! Happy Father's Day Joel!' Although Schiffman and Kotb once lived together in New York City with their kids, the mother of two made the decision in 2024 to move her children to the suburbs in a bid to give them more 'normality,' while it's thought her former partner remained in Manhattan. However, he made sure to take a break from the honking taxis and towering skyscrapers to make a trip to Bronxville, which is a mere 30-minute drive from Manhattan. Schiffman's journey upstate comes just weeks after Kotb revealed that her move had been motivated, at least in part, by her daughter Hope's Type 1 diabetes diagnosis. During a May 28 appearance on 'Today,' Kotb explained there was another reason behind her decision, conceding that she wanted to spend more time with her daughter, rather than worrying about her health constantly because she was away from her. 'As anyone with a child who has Type 1 [diabetes], especially a little kid, you're constantly watching, you're constantly monitoring, you're constantly checking, which is what I did all the time when I was [on the 'Today' show]. You're distracted,' she shared. 'You just get a priority check in your life. I can be here and sweating what's happening to Hope in the morning and in the night, or I can be there and feel relief that I can see.' Kotb first revealed that her younger daughter was struggling with a health issue in March 2023, when she explained that Hope had been hospitalized for an undisclosed condition. Less than two years later, Kotb decided to move her family to Bronxville, NY, where she purchased a stunning $2.9 million property just a short walk from her kids' school. Speaking to ahead of her last day on the show, Kotb opened up about her desire to embrace a new routine with her kids at the four-bedroom, five-bathroom, center-hall Colonial. She was excited to have a more 'normal' day-to-day regimen after years of early mornings, she explained. 'I'm just going to let us be a family with a normal rhythm of life. See what we become,' the on-air celebrity, who was replaced by Craig Melvin, said. 'I'm going to let [my daughters] take more trips and stay up a little later because part of the reason I put them to bed at that hour is because I've got to go to bed. I'm like, 'Goodnight! Everyone's going to bed.' They're like, 'It's 6:30!' I'm like, 'Yeah, lights out!'' Kotb said in August that she had a vision when it came to finding the perfect family home, revealing in an episode of 'Today' that she wanted to create a 'warm and cozy' environment where her children could relax and find sanctuary. 'It's all new,' she said of her move. 'New kids, new school, new things, new everything. And it's funny because all I could think of was that I wanted my house for the kids to feel warm and cozy and a place where they want to hang. And that's it.' She added in an interview with People: 'I want my kids to feel grass on their feet, and play in the yard, and ride bikes down the street, and run up and down the stairs.' In October, just a few months after her move, Kotb further shared how moving to the suburbs had helped Hope to overcome her severe health issues—albeit without disclosing what those issues were. 'We're in a place where Hope is thriving,' noted Kotb. 'She's improving, we're watching her, and I think as time goes on, we'll have a better handle on it, but we're already seeing great differences. 'I have people helping us out. I feel like she is finding steady footing.' Now, Kotb is focusing on her new wellness brand, Joy 101, which allows people to achieve more grounded and calming lifestyles. Just weeks ago, she revealed that she had paired up with HGTV icon Joanna Gaines to transform her wellness office space. Families Are Sticking Together: Multigenerational Homebuying Hits an All-Time High as Americans Battle Soaring Cost of Living Home Listings Flooding the Market Are Giving Buyers More Options 'My Sellers Lost $10K After Their Home Was Relisted'—Here's How You Can Prepare
